| Home | E-Submission | Sitemap | Contact Us |  
Korean J Med > Volume 87(1); 2014 > Article
The Korean Journal of Medicine 2014;87(1): 14-18.
Sodium Glucose Co-Transporter 2 (SGLT2) 억제제
김미경, 박정현
인제대학교 의과대학 내과학교실, 백인제기념임상의학연구소
Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitor
Mi-kyung Kim, Jeong Hyun Park
Paik Institute for Clinical Research, Department of Internal Medicine, Inje University College of Medicine, Busan, Korea
Corresponding Author: Jeong Hyun Park ,Tel: +82-51-890-6074, Fax: +82-51-892-0273, Email: pjhdoc@chol.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Sodium glucose co-transporter 2 (SGLT2) inhibition is a new therapeutic approach for the treatment of type 2 diabetes mellitus, independent of insulin secretion and activity. SGLT2 inhibitors have a unique mechanism of action via inhibition of renal glucose reabsorption, which is different from the mechanisms of prior medications. Clinical trials have supported the efficacy of SGLT2 inhibitors in the reduction of HbA1c as monotherapy or add-on therapy with other existing medications, including insulin. In addition to their glucose-lowering effect, SGLT2 inhibitors can significantly reduce blood pressure and body weight. The most concerning side effects are genital and urinary tract infections, especially in females. SGLT2 inhibitors offer a promising potential strategy for diabetes treatment because they can be combined with nearly any existing anti-diabetic medication, cause less hypoglycemia, and possess additional metabolic benefits beyond glucose level reduction.
Keywords: Type 2 Diabetes; Renal glucose reabsorption; SGLT2 inhibitors; Urinary tract infection; Genital infection
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
Supplementary Material  Supplementary Material
Editorial Office
101-2501, Lotte Castle President, 109 Mapo-daero, Mapo-gu, Seoul 04146, Korea
Tel: +82-2-2271-6791   Fax: +82-2-790-0993    E-mail: kaim@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association of Internal Medicine. All rights reserved.                powerd by m2community